Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia

Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan

Status and phase

Unknown

Phase 4

Conditions

Dyskinesia, Drug-Induced

Treatments

Drug: aripiprazole

Study type

Interventional

Funder types

Other

Identifiers

NCT00837707

TMH-97-03

Details and patient eligibility

About

The aim of the present study was to investigate the efficacy of aripiprazole in management of pre-existing neuroleptic-induced tardive dyskinesia

Full description

Objective:A few case reports on the use of aripiprazole in neuroleptic-induced tardive dyskinesia have demonstrated positive effects. However its effectiveness in treatment of TD was still inconclusive. The aim of the present study was to investigate the efficacy of aripiprazole in management of pre-existing neuroleptic-induced tardive dyskinesia.

Method: Subjects with pre-existing neuroleptic-induced tardive dyskinesia were chosen from Taoyuan psychiatric center. Patients recruited would be treated with aripiprazole for cross-titration with previous antipsychotics in 8 weeks. We use AIMS, SAS, & BAS to assess the severity of TF and EPS. We record subjects' age, sex, and other factors which have influence at the treatment response. Subjects are assessed every two weeks in the first month and then monthly until six months.

Enrollment

25 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

Female patients must agree to prevent from being pregnant during trial periods
Meet psychotic disorder or mood disorder criteria of DSM-IV
Patients must have psychiatric diseases that need to use antipsychotics for a long time
They must meet DSM-IV research criteria for neuroleptics induce tardive dyskinesia
No clinical significant major systemic diseases
No special neurological diseases which would influence the assessment for EPS or TD
Mentality is better than mild mental retardation
Patients or .legal representatives agree to join in the research and sign informed consent.

Exclusion criteria

Unstable major systemic diseases
Had neurological disorder influenced to EPS assessment
Substance abuse or dependence other then coffee or tobacco within 6 months before study